Vikram Arora, MD
Cardiovascular Disease · Birmingham, ALNPI 1255335246
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $234,623 of the $270,676 with a category attached, or 86.7%. 40 manufacturers reported payments, led by Boehringer Ingelheim at 37.7% of the total. Among cardiovascular disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 674 payments — averaging $401.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$102K
- Lilly USA, LLC$44K
- AstraZeneca$29K
- Amarin Pharma, Inc.$29K
- Esperion Therapeutics, Inc.$23K
- Bayer$14K
- plus $30K from 34 others
Across 79 payments — averaging $6833.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$279K
- Amgen$66K
- Boehringer Ingelheim International GmbH$61K
- Boston Scientific$60K
- Boehringer Ingelheim Pharma GmbH & Co.kg$59K
- Janssen Research & Development, LLC$15K
What the payments were for
- Consulting fees$3,3751%
- Speaking & faculty fees$234,62387%
- Travel & lodging$20,2137%
- Food & beverage$12,2565%
- Education$1960%
- Entertainment$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 144 | $102,013 |
| Lilly USA, LLC | 40 | $43,563 |
| AstraZeneca | 45 | $28,967 |
| Amarin Pharma, Inc. | 37 | $28,883 |
| Esperion Therapeutics, Inc. | 23 | $22,956 |
| Bayer | 11 | $14,025 |
| Astellas Pharma US Inc | 14 | $13,327 |
| Novartis | 115 | $10,587 |
| Ancora Heart, Inc. | 5 | $1,755 |
| Abbott | 73 | $1,077 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 36 | $527 |
| Actelion Pharmaceuticals US, Inc. | 31 | $445 |
| Medtronic(2 entities) | 6 | $354 |
| Pfizer | 16 | $288 |
| Cvrx, Inc. | 5 | $257 |
| Amgen | 16 | $209 |
| Inari Medical, Inc. | 3 | $191 |
| Impulse Dynamics (USA) Inc. | 10 | $169 |
| Edwards Lifesciences | 2 | $155 |
| Vertos Medical, Inc. | 1 | $127 |
| Vital Connect, Inc | 1 | $127 |
| Sanofi-aventis U.S. LLC | 6 | $101 |
| Johnson & Johnson | 7 | $97 |
| Irhythm Technologies, Inc. | 4 | $70 |
| AbbVie | 3 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Abiomed | 2 | $55 |
| Vifor Pharma, Inc. | 2 | $29 |
| Lantheus Medical Imaging, Inc. | 1 | $22 |
| Livanova USA, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Sobi, Inc | 1 | $16 |
| CSL Behring | 1 | $16 |
| Akcea Therapeutics, Inc. | 1 | $15 |
| Optos, Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Novo Nordisk | 1 | $13 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$144,136
- Vascepa$28,246
- NEXLIZET$22,676
- NEXLETOL$22,676
- FARXIGA$18,684
- Kerendia$13,993
- LOKELMA$9,702
- ENTRESTO$9,079
- LEXISCAN$8,426
- AccuCinch$1,705
- FLOWTRIEVER CATHETER, S$312
- MitraClip System$274
- Barostim Neo System$243
- INTELLIS$242
- mild Device Kit$127
- VITALPATCH RTM$127
- SAPIEN 3 Ultra RESILIA$122
- MitraClip$105
- CardioMEMS HF System$104
- LifeVest$102
How this compares
$270,676 in reported general payments places this provider in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 108 | $1,374,913 |
| EliquisApixaban | 677 | $559,249 |
| JardianceEmpagliflozin | 460 | $415,472 |
| UptraviSelexipag | 17 | $402,913 |
| Tyvaso DpiTreprostinil | 16 | $364,836 |
| EntrestoSacubitril/Valsartan | 298 | $298,543 |
| OzempicSemaglutide | 126 | $181,858 |
| XareltoRivaroxaban | 188 | $171,250 |
| MounjaroTirzepatide | 64 | $81,619 |
| FarxigaDapagliflozin Propanediol | 86 | $80,402 |
| Repatha SureclickEvolocumab | 97 | $68,646 |
| Orenitram ErTreprostinil Diolamine | 11 | $66,587 |
| MultaqDronedarone Hcl | 60 | $59,549 |
| VascepaIcosapent Ethyl | 57 | $32,213 |
| Icosapent Ethyl | 75 | $29,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $445 | $1,777,827125 claims |
| PfizerEliquis | $288 | $559,249677 claims |
| Boehringer IngelheimJardiance | $102,013 | $415,472460 claims |
| NovartisEntresto | $10,587 | $298,543298 claims |
| Novo NordiskOzempic | $13 | $181,858126 claims |
| Johnson & JohnsonXarelto | $97 | $171,250188 claims |
| Lilly USA, LLCMounjaro, Trulicity | $43,563 | $108,56792 claims |
| AstraZenecaFarxiga | $28,967 | $80,40286 claims |
| Sanofi-aventis U.S. LLCMultaq | $101 | $59,54960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Birmingham
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Thomas CawthonBirmingham$54K
- Weihan ChenBirmingham$51K
- Farrell MendelsohnBirmingham$51K
- Charles MooreBirmingham$47K
- Christopher DegroatBirmingham$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.